Thyroid News and Research RSS Feed - Thyroid News and Research

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data finds fivefold increase in thyroid cancer rates

New Cancer Council data has found a fivefold increase in rates of thyroid during the past 30 years in Queensland, with nearly 500 Queenslanders diagnosed in 2012 compared to less than 50 diagnoses in 1982. [More]
Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors. [More]
Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

Endocrine disrupting chemicals can alter thyroid levels in pregnant women, may affect fetus

A new study led by biologist R. Thomas Zoeller of the University of Massachusetts Amherst provides "the strongest evidence to date" that endocrine disrupting chemicals such as polychlorinated biphenyls (PCB) found in flame retardant cloth, paint, adhesives and electrical transformers, can interfere with thyroid hormone action in pregnant women and may travel across the placenta to affect the fetus. [More]
Mercy Medical Center partners with Everseat to employ new scheduling platform for Women's Services

Mercy Medical Center partners with Everseat to employ new scheduling platform for Women's Services

Mercy Medical Center has announced that it has entered into an agreement with Everseat to employ an all new mobile scheduling platform for its Women's Services, including: Gynecology, Gynecologic Oncology, Breast Disease and Breast Cancer, Imaging Services such as mammograms, and Endocrinology, including diabetes, thyroid and bone health. [More]
Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin should not be dismissed as a mild condition and is worth screening for, say researchers. [More]
Lithium therapy duration not linked to thyroid effects

Lithium therapy duration not linked to thyroid effects

The risk of altered thyroid function does not increase with duration of lithium treatment in patients with bipolar disorder, research suggests. [More]
New approach to fighting breast, thyroid cancers

New approach to fighting breast, thyroid cancers

A team of researchers from the University of Alberta has discovered a new approach to fighting breast and thyroid cancers by targeting an enzyme they say is the culprit for the "vicious cycle" of tumour growth, spread and resistance to treatment. [More]
Research reveals critical role natural antioxidant selenium plays in woman's fertility

Research reveals critical role natural antioxidant selenium plays in woman's fertility

University of Adelaide research has for the first time shown how much of a critical role the natural antioxidant selenium plays at the earliest stages of a woman's fertility. [More]
Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. [More]
UNC researchers develop new approach to block KRAS oncogene

UNC researchers develop new approach to block KRAS oncogene

Researchers from the UNC School of Medicine and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer. [More]
Worst effects of reperfusion injury after heart attack may be prevented with iodide

Worst effects of reperfusion injury after heart attack may be prevented with iodide

Blocked arteries are typically the trigger, stopping the flow of blood and starving the heart muscle of oxygen. But when the blockage is removed and the blood comes rushing back, it wreaks havoc of its own. The result is called reperfusion injury, a life-threatening flood of inflammation and cellular destruction that has stumped scientists for 40 years. [More]
Medical illness common in bipolar disorder

Medical illness common in bipolar disorder

Patients with bipolar disorder have high rates of medical illness, which often exceeds the levels observed in patients with unipolar depression, show results of a UK-based study. [More]
University Medical Center's first atrial fibrillation unit opens in Germany

University Medical Center's first atrial fibrillation unit opens in Germany

Nearly 1.8 million people in Germany suffer from atrial fibrillation. This is the most common and clinically significant form of heart rhythm disorder. Shortness of breath, a sudden sense of dizziness, a feeling of pressure in the chest, and palpitations or thumping of the heart so extreme it can be felt beating rapidly and irregularly - this is how many patients describe their first episode of atrial fibrillation. [More]
Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

Study on papillary thyroid carcinoma to be presented at 84th Annual Meeting of the ATA

The prevalence of papillary thyroid carcinoma (PTC), the most common type of thyroid cancer, is increasing rapidly. New research to determine the impact of radioactive iodine (RAI) therapy on survival in PTC, describing a novel blood test able to detect circulating BRAFV600E-positive tumor DNA, and identifying a long non-coding RNA specifically associated with the thyroid that is down-regulated in PTC compared to normal thyroid tissue in patient-derived clinical specimens and cell cultures will be featured in oral presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve thyroid cancer outcomes

Novel therapeutic approaches to improve outcomes in thyroid cancer, for example using targeted delivery of cytotoxic drugs to tumor cells, will be among the topics featured in oral and poster presentations delivered at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
New research findings on Graves' disease to be highlighted at ATA meeting

New research findings on Graves' disease to be highlighted at ATA meeting

A unique mouse model of Graves' disease, an autoimmune disorder that causes hyperthyroidism, and new research findings that may help improve the treatment of Graves' disease will be highlighted in oral and poster presentations at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California. [More]
Understanding of genomic landscape of thyroid cancer

Understanding of genomic landscape of thyroid cancer

A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas Research Network has identified markers of aggressive tumors, which could allow for better targeting of appropriate treatments to individual patients. [More]
Study reveals subtypes, potential diagnostic and treatment clues for papillary thyroid carcinomas

Study reveals subtypes, potential diagnostic and treatment clues for papillary thyroid carcinomas

A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) – the most common form of thyroid cancer – has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development. [More]

Hand blenders can emit chlorinated paraffins during normal household use

Eight out of twelve tested models of hand blenders are leaking chlorinated paraffins when used according to the suppliers' instructions. [More]